MX2023008027A - Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas. - Google Patents
Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas.Info
- Publication number
- MX2023008027A MX2023008027A MX2023008027A MX2023008027A MX2023008027A MX 2023008027 A MX2023008027 A MX 2023008027A MX 2023008027 A MX2023008027 A MX 2023008027A MX 2023008027 A MX2023008027 A MX 2023008027A MX 2023008027 A MX2023008027 A MX 2023008027A
- Authority
- MX
- Mexico
- Prior art keywords
- sialidase
- fusion proteins
- her2
- methods
- antibody fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134411P | 2021-01-06 | 2021-01-06 | |
| US202163217998P | 2021-07-02 | 2021-07-02 | |
| PCT/US2022/011499 WO2022150516A1 (en) | 2021-01-06 | 2022-01-06 | Sialidase-her2-antibody fusion proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008027A true MX2023008027A (es) | 2023-09-05 |
Family
ID=82357542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008027A MX2023008027A (es) | 2021-01-06 | 2022-01-06 | Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240059792A1 (https=) |
| EP (1) | EP4274892A4 (https=) |
| JP (1) | JP2024501767A (https=) |
| KR (1) | KR20230138473A (https=) |
| AU (1) | AU2022206263A1 (https=) |
| CA (1) | CA3173668A1 (https=) |
| IL (1) | IL304233A (https=) |
| MX (1) | MX2023008027A (https=) |
| WO (1) | WO2022150516A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022006492A2 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081801B2 (en) * | 2013-04-12 | 2018-09-25 | Danmarks Tekniske Universitet | Mutant sialidase having trans-sialidase activity for use in production of sialylated glycans |
| KR102914621B1 (ko) * | 2018-01-03 | 2026-01-21 | 팔레온 파마슈티칼스 인크. | 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법 |
| WO2020142727A1 (en) * | 2019-01-03 | 2020-07-09 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| WO2020172072A1 (en) * | 2019-02-21 | 2020-08-27 | The General Hospital Corporation | Glycoengineering immunoglobulin e |
| CA3135531A1 (en) * | 2019-04-30 | 2020-11-05 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022006492A2 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| US20240067729A1 (en) * | 2021-01-06 | 2024-02-29 | Palleon Pharmaceuticals Inc. | Anti-pd-l1 antibodies and fusion proteins thereof |
-
2022
- 2022-01-06 WO PCT/US2022/011499 patent/WO2022150516A1/en not_active Ceased
- 2022-01-06 JP JP2023540918A patent/JP2024501767A/ja not_active Withdrawn
- 2022-01-06 EP EP22737130.9A patent/EP4274892A4/en not_active Withdrawn
- 2022-01-06 US US18/260,383 patent/US20240059792A1/en active Pending
- 2022-01-06 MX MX2023008027A patent/MX2023008027A/es unknown
- 2022-01-06 AU AU2022206263A patent/AU2022206263A1/en not_active Abandoned
- 2022-01-06 KR KR1020237026706A patent/KR20230138473A/ko not_active Withdrawn
- 2022-01-06 CA CA3173668A patent/CA3173668A1/en active Pending
-
2023
- 2023-07-04 IL IL304233A patent/IL304233A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304233A (en) | 2023-09-01 |
| US20240059792A1 (en) | 2024-02-22 |
| JP2024501767A (ja) | 2024-01-15 |
| EP4274892A4 (en) | 2025-03-12 |
| CA3173668A1 (en) | 2022-07-14 |
| WO2022150516A1 (en) | 2022-07-14 |
| KR20230138473A (ko) | 2023-10-05 |
| AU2022206263A1 (en) | 2023-07-20 |
| EP4274892A1 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015880A (es) | Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos. | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| CR20200579A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20211491A1 (es) | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2024001803A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| MX2022003517A (es) | Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco. | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| CO2023015593A2 (es) | Terapias basadas en il2 y métodos de uso de las mismas | |
| CO2024013569A2 (es) | Moléculas de unión contra frα | |
| CO2022013937A2 (es) | Agentes de fijación a tie2 y métodos de uso | |
| CO2022008314A2 (es) | Anticuerpos anti–mertk y métodos de uso de los mismos | |
| MX2023008027A (es) | Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas. | |
| MX2023008028A (es) | Anticuerpos anti-pd-l1 y proteinas de fusion de estos. | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| CO2022015049A2 (es) | Péptidos de dominios knob autónomos | |
| CO2023001559A2 (es) | Anticuerpos fgfr3 y métodos de uso | |
| AR115257A1 (es) | Anticuerpos de fijación a bcma y sus usos | |
| MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
| MX2023008029A (es) | Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas. |